05:36 PM EDT, 05/22/2025 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said its Hydronidone compound to treat liver fibrosis in patients with chronic hepatitis B met the primary endpoint in the phase 3 trial in China.

The 52-week trial revealed that almost 53% of patients receiving Hydronidone achieved 1-stage regression in liver fibrosis versus placebo, Gyre said Thursday in a statement.

The drug was well tolerated with no discontinuations due to adverse events, the company said.

Gyre plans to present full trial results at a medical congress and file a new drug application with China's National Medical Products Administration in Q3.

In a separate statement, Gyre announced a proposed underwritten public share offering with proceeds to advance its Phase 2 clinical trial of F351 in the US to treat liver fibrosis, among other things.

Gyre shares fell 15% in after-hours trading.